PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.69%
Revenue growth under 50% of 3141.T's 23.03%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
1.43%
Gross profit growth under 50% of 3141.T's 25.26%. Michael Burry would be concerned about a severe competitive disadvantage.
10.35%
Positive EBIT growth while 3141.T is negative. John Neff might see a substantial edge in operational management.
2.77%
Positive operating income growth while 3141.T is negative. John Neff might view this as a competitive edge in operations.
10.77%
Positive net income growth while 3141.T is negative. John Neff might see a big relative performance advantage.
10.76%
Positive EPS growth while 3141.T is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
10.76%
Positive diluted EPS growth while 3141.T is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.00%
Share reduction while 3141.T is at 14.42%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3141.T is at 14.42%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
25.00%
10Y revenue/share CAGR under 50% of 3141.T's 127.56%. Michael Burry would suspect a lasting competitive disadvantage.
-4.42%
Negative 5Y CAGR while 3141.T stands at 62.43%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-31.64%
Negative 3Y CAGR while 3141.T stands at 32.83%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
100.00%
10Y OCF/share CAGR in line with 3141.T's 100.00%. Walter Schloss would see both as similarly efficient over the decade.
100.00%
5Y OCF/share CAGR is similar to 3141.T's 100.00%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
No Data
No Data available this quarter, please select a different quarter.
128.06%
Net income/share CAGR at 50-75% of 3141.T's 188.21%. Martin Whitman might question if the firm’s product or cost base lags behind.
16.10%
Below 50% of 3141.T's 153.83%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-24.32%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
93.99%
Equity/share CAGR of 93.99% while 3141.T is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
30.55%
Below 50% of 3141.T's 120.58%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-14.41%
Negative 3Y equity/share growth while 3141.T is at 67.91%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.45%
Firm’s AR is declining while 3141.T shows 41.47%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-2.50%
Inventory is declining while 3141.T stands at 43.54%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-0.38%
Negative asset growth while 3141.T invests at 30.73%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
3.50%
Under 50% of 3141.T's 10.17%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-0.73%
We’re deleveraging while 3141.T stands at 58.87%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
1.10%
SG&A declining or stable vs. 3141.T's 29.76%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.